Browsing Wolfson Institute of Preventive Medicine by Author "O'Donovan, M"
Now showing items 1-6 of 6
-
634 RESULTS FROM THE BARRETT'S OESOPHAGUS TRIAL 3 (BEST3): A RANDOMISED CONTROLLED TRIAL COMPARING THE CYTOSPONGE™-TFF3 TEST WITH USUAL CARE TO IDENTIFY OESOPHAGEAL PRECANCER IN PRIMARY CARE PATIENTS WITH CHRONIC GASTROESOPHAGEAL REFLUX
Fitzgerald, RC; Di Pietro, M; O'Donovan, M; Muldrew, B; Debiram-Beecham, I; Offman, J; Baseley, L; Smith, SG; Aigret, B; Walter, FM (2020-05-01)AGA Abstract -
861 MODELLING FROM A MULTICENTRE, PRAGMATIC, RANDOMISED CONTROLLED TRIAL IDENTIFIES THE TARGET SCREENING POPULATION AND EXPECTED YIELD FOR BARRETT'S ESOPHAGUS AND ESOPHAGEAL CANCER DIAGNOSES
Tan, WK; Maroni, R; Offman, J; Zamani, S; Di Pietro, M; O'Donovan, M; Sasieni, P; Fitzgerald, RC (Elsevier, 2024-05) -
FEASIBILITY OF THE IMPLEMENTATION OF CYTOSPONGE AS A TRIAGE TEST FOR REFLUX SYMPTOMS IN PRIMARY CARE: BARRETT'S ESOPHAGUS SCREENING TRIAL 3 (BEST3)
Wilson, A; Debiram-Beecham, I; Bowers, B; Muldrew, B; Aigret, B; O'Donovan, M; Tripathi, M; Offman, J; Smith, S; Jackson, C (2018-05) -
IDEAL AGE TO SCREEN FOR BARRETT'S OESOPHAGUS AND OESOPHAGEAL ADENOCARCINOMA: MODELLING FROM THE CYTOSPONGE-BEST3 TRIAL
Tan, WK; Maroni, R; Offman, J; di Pietro, M; Honing, J; O'Donovan, M; Sasieni, P; Fitzgerald, R (2022) -
Sa1643 - Feasibility of the Implementation of Cytosponge as a Triage Test for Reflux Symptoms in Primary Care: Barrett's Esophagus Screening Trial 3 (Best3)
Wilson, A; -Beecham, ID; Bowers, B; Muldrew, B; Aigret, B; O'Donovan, M; Tripathi, M; Offman, J; Smith, S; Jackson, C (2018-05-01) -
Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot
Pilonis, ND; Killcoyne, S; Tan, WK; O'Donovan, M; Malhotra, S; Tripathi, M; Miremadi, A; Debiram-Beecham, I; Evans, T; Phillips, R (Elsevier, 2022-01-11)Background Endoscopic surveillance is recommended for patients with Barrett's oesophagus because, although the progression risk is low, endoscopic intervention is highly effective for high-grade dysplasia and cancer. ...